ReviewFrontiers in immunology2026
Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy, as the fourth major cancer treatment method, has made breakthrough progress in the field of cancer therapy. Immune checkpoint inhibitors (ICIs) have been extensively utilized in the management of diverse malignant neoplasms, with a substantial corpus of clinical evidence and experience accumulating in the field of gynecological oncology. This article reviews the clinical application strategies of ICIs, either alone or in combination with radiotherapy and chemotherapy, targeted therapy, etc., for gynecological malignant tumors such as cervical cancer, endometrial cancer, ovarian cancer, and other malignancies. We summarized relevant progress from clinical trials with the aim of providing more effective precision immunotherapy strategies for patients with gynecological malignant tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.